HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eduardo Aluicio-Sarduy Selected Research

Prostatic Neoplasms (Prostate Cancer)

3/2024"Off-Label Use" of the Siderophore Enterobactin Enables Targeted Imaging of Cancer with Radioactive Ti(IV).
1/2023Copper-Mediated Radiobromination of (Hetero)Aryl Boronic Pinacol Esters.
1/2022Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors.
12/2021A High Separation Factor for 165Er from Ho for Targeted Radionuclide Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Eduardo Aluicio-Sarduy Research Topics

Disease

23Neoplasms (Cancer)
03/2024 - 01/2018
4Prostatic Neoplasms (Prostate Cancer)
03/2024 - 12/2021
2Adenocarcinoma
03/2023 - 12/2022
2Breast Neoplasms (Breast Cancer)
01/2021 - 01/2018
2Melanoma (Melanoma, Malignant)
01/2021 - 01/2021
2Neoplasm Metastasis (Metastasis)
01/2021 - 01/2020
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2024
1Neuroinflammatory Diseases
12/2021
1Brain Neoplasms (Brain Tumor)
01/2021
1Bites and Stings (Sting)
01/2021
1Osteosarcoma (Osteogenic Sarcoma)
01/2021
1Triple Negative Breast Neoplasms
01/2020
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2020
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2019

Drug/Important Bio-Agent (IBA)

9Radioisotopes (Radionuclides)IBA
01/2022 - 01/2019
4RadiopharmaceuticalsIBA
02/2024 - 12/2018
3Immune Checkpoint InhibitorsIBA
01/2021 - 01/2021
3Monoclonal AntibodiesIBA
01/2021 - 01/2018
2Peptides (Polypeptides)IBA
03/2024 - 12/2022
2IsotopesIBA
03/2024 - 01/2018
2Neurotensin Receptors (Neurotensin Receptor)IBA
03/2023 - 12/2022
2CytokinesIBA
01/2021 - 01/2021
1Proto-Oncogene Proteins c-metIBA
03/2024
1Single-Domain AntibodiesIBA
03/2024
1SiderophoresIBA
03/2024
1AntigensIBA
03/2024
1EnterobactinIBA
03/2024
1Cobalt-55IBA
10/2023
1Photosensitizing Agents (Photosensitizers)IBA
08/2023
1PolymersIBA
08/2023
1NeurotensinIBA
03/2023
11,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
03/2023
1lysylprolineIBA
03/2023
1Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2023
1Staphylococcal Protein A (Protein A)IBA
12/2021
1Biomarkers (Surrogate Marker)IBA
12/2021
1Interleukin-13IBA
01/2021
1InterferonsIBA
01/2021
1Interleukin-2 (IL2)IBA
01/2021
1Yttrium-86IBA
01/2021
1lorukafusp alfaIBA
01/2021
1Silicon Dioxide (Silica)FDA LinkGeneric
01/2021
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
01/2021
1Interleukin-10 (Interleukin 10)IBA
01/2021
1ChemokinesIBA
01/2021
1Chelating AgentsIBA
01/2020
1Excipients (Suspending Agents)IBA
01/2020
1Thromboplastin (Tissue Factor)IBA
01/2020
1carotuximabIBA
01/2018

Therapy/Procedure

14Therapeutics
08/2023 - 01/2018
10Precision Medicine
10/2023 - 01/2018
6Radiotherapy
01/2022 - 11/2019
4Immunotherapy
01/2022 - 11/2019
1Off-Label Use
03/2024
1Intravenous Administration
01/2022
1Injections
01/2021
1Drug Therapy (Chemotherapy)
01/2018
1Molecular Targeted Therapy
01/2018